Login to Your Account



Investors Like the News; Stock Rockets 63%

Study Confirms Efficacy of CBLI Radiation Countermeasure

By Catherine Shaffer
Staff Writer

Tuesday, June 5, 2012
Stock in Cleveland Biolabs Inc. surged 63 percent following the release of results from its efficacy study of radiation countermeasure product, CBLB502, showing a nearly threefold increase in overall survival among rats exposed to a 70 percent lethal dose of radiation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription